The role of Ekoxinal in the treatment of infertility

Authors

  • А. М. Феськов Human reproduction center «Sana-Med», Kharkiv, Ukraine
  • И. М. Безпечная Human reproduction center «Sana-Med», Kharkiv, Ukraine
  • И. А. Феськова Human reproduction center «Sana-Med», Kharkiv, Ukraine
  • В. В. Лазуренко Kharkiv National Medical University, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2019.46.68-70

Keywords:

infertility, myo-inositol, Ekoxinal

Abstract

The effective treatment of infertility and an increase in the effectiveness of ART is a current problem of modern reproductive medicine, and therefore, is the important task is to clarify the possibility of using drugs containing myo-inositol to treat infertility caused by sperm hypomotility.

The purpose of study was to define the role of Ecoxinal suppositories in infertility treatment in a natural way.

We examined 80 married couples with unexplained infertility, that lasted from 1 to 4 years (main group). The control group consisted of 30 married couples who do not suffer from infertility. The patients of the main group were divided into two clinical groups of 40 women in each group by the randomized method. Patients of the first clinical group tried to get pregnant without taking myo-inositol. Patients of the second clinical group received Ecoxinal (contains 2 mg of myo-inositol) intravaginally in the form of suppositories during the periovulatory period (from 11 to 16 days with a 28-day menstrual cycle) when the diameter of the dominant follicle is more than 16 mm. All female patients were examined and treated on the background of a natural or induced ovulation cycles.

As a result of the study, it was found that intravaginal use of Ecoxinal suppositories in fertile women whose husbands suffer from infertility (oligoasthenospermia) significantly increases the pregnancy rate to 22.5%.

The conditions for intravaginal use of Epoxial suppositories are passable fallopian tubes with preserved fimbrial sections and spermograms of actively motile spermatozoa of at least 3.7 ± 2.1 million/ml, and in the case of treatment using the swim up method, they should be at least 10 million/ml.

Author Biographies

А. М. Феськов, Human reproduction center «Sana-Med», Kharkiv

MD, professor, director

И. М. Безпечная, Human reproduction center «Sana-Med», Kharkiv

Reproductologist, head of IVF department

И. А. Феськова, Human reproduction center «Sana-Med», Kharkiv

PhD, reproductologist, medical director

В. В. Лазуренко, Kharkiv National Medical University

MD, professor, head of Obstetrics and Gynecology department №2

References

  1. Fisher, J.R.W., Hammarberg, K. “Psychological and social aspects of infertility in men: an overview of the evidence and implications for psychologically informed clinical care and future research.” Asian Journal of Andrology 14.1 (2012): 121–9.
  2. Singh, K., Jaiswal, D. “Human male infertility: a complex multifactorial phenotype.” Reproductive Sciences 18.5 (2011): 418–25.
  3. Aitken, R.J. “Sperm function tests and fertility.” International Journal of Andrology 29.1 (2006): 69–108.
  4. Artini, P.G., Casarosa, E., Carletti, E., et al. “In vitro effect of myo-inositol on sperm motility in normal and oligoasthenospermia patients undergoing in vitro fertilization.” Gynecol Endocrinol 33.2 (2017): 109–12.
  5. Calogero, A.E., Gullo, G., Vignera, S., et al. “Myo-inositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study.” Andrology 3.3 (2015): 491–5.
  6. Montanino Oliva, M., Poverini, R., Lisi, R., et al. Treating Woman with Myo-Inositol Vaginal Suppositories Improves Partner’s Sperm Motility and Fertility. Hindawi Publishing Corporation International Journal of Endocrinology (2016): 5 p.
  7. Condorelli, R.A., La Vignera, S., Di Bari, F., et al. “Effects of myoinositol on sperm mitochondrial function in- vitro.” Eur Rev Med Pharmacol Sci 15 (2011): 129–34.
  8. Marchetti, P., Ballot, C., Jouy, N., et al. “Influence of mitochondrial membrane potential of spermatozoa on in vitro fertilisation outcome.” Andrology 44 (2012): 136–41.
  9. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen (5th edition). WHO. Geneva, Switzerland (2010).

Downloads

Published

2019-05-21

How to Cite

Феськов, А. М., Безпечная, И. М., Феськова, И. А., & Лазуренко, В. В. (2019). The role of Ekoxinal in the treatment of infertility. REPRODUCTIVE ENDOCRINOLOGY, (46), 68–70. https://doi.org/10.18370/2309-4117.2019.46.68-70

Issue

No. 46 (2019)

Section

Drug therapy

License

Copyright (c) 2019 А. М. Феськов, И. М. Безпечная, И. А. Феськова, В. В. Лазуренко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.